{"organizations": [], "uuid": "050f64c4596a2fa65d95b4537bf76deeaf122a6f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-health-canada-approves-rituxan-sub/brief-health-canada-approves-rituxan-subcutaneous-formulation-for-canadians-with-chronic-lymphocytic-leukemia-idUSFWN1R40PJ", "country": "US", "domain_rank": 408, "title": "BRIEF-Health Canada Approves Rituxan Subcutaneous Formulation For Canadians With Chronic Lymphocytic Leukemia", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-22T14:18:00.000+02:00", "replies_count": 0, "uuid": "050f64c4596a2fa65d95b4537bf76deeaf122a6f"}, "author": "", "url": "https://www.reuters.com/article/brief-health-canada-approves-rituxan-sub/brief-health-canada-approves-rituxan-subcutaneous-formulation-for-canadians-with-chronic-lymphocytic-leukemia-idUSFWN1R40PJ", "ord_in_thread": 0, "title": "BRIEF-Health Canada Approves Rituxan Subcutaneous Formulation For Canadians With Chronic Lymphocytic Leukemia", "locations": [], "entities": {"persons": [{"name": "hoffmann-la roche", "sentiment": "none"}], "locations": [{"name": "canada", "sentiment": "none"}, {"name": "canada", "sentiment": "none"}], "organizations": [{"name": "brief-health canada approves rituxan subcutaneous", "sentiment": "negative"}, {"name": "roche holding ag", "sentiment": "none"}, {"name": "chronic lymphocytic leukemia reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 22, 2018 / 12:18 PM / Updated 13 minutes ago BRIEF-Health Canada Approves Rituxan Subcutaneous Formulation For Canadians With Chronic Lymphocytic Leukemia Reuters Staff March 22 (Reuters) - Roche Holding AG: * HEALTH CANADA APPROVES RITUXAN® SUBCUTANEOUS FORMULATION FOR CANADIANS WITH CHRONIC LYMPHOCYTIC LEUKEMIA * ‍HOFFMANN-LA ROCHE - HEALTH CANADA APPROVES RITUXAN SC FORMULATION FOR CANADIANS WITH CHRONIC LYMPHOCYTIC LEUKEMIA​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-22T14:18:00.000+02:00", "crawled": "2018-03-22T14:34:13.017+02:00", "highlightTitle": ""}